Center of Excellence
The Seattle Cancer Care Alliance is one of the nation's top cancer centers. Mesothelioma specialists, surgeons and thoracic oncologists are constantly working on various clinical trials involving immunotherapy and other emerging treatments to help survivors live beyond their life expectancy.Get in touch
The Seattle Cancer Care Alliance (SCCA) has come a long way in a relatively short period of time, quickly carving a niche for itself as one of the top treatment centers in the U.S.
In 1998, the SCCA opened originally as a collaborative effort of the Fred Hutchinson Cancer Research Center, the University of Washington Medical Center and Seattle Children’s Hospital.
That cancer-fighting trio turns scientific discoveries into innovative treatments, prevention breakthroughs and cures that drawn rave reviews from the medical community.
For more than a decade, U.S. News and World Report has ranked SCCA/University of Washington Medical Center among the nation’s top 10 Best Hospitals for Cancer Care in its annual report.
The SCCA network includes seven facilities throughout Washington and four more in Alaska, Hawaii, Idaho and Montana, along with community-based physicians throughout the area.
It provides access to myriad resources, including clinical trials, throughout the Pacific Northwest.
SCCA has a dedicated team working to combat mesothelioma, the rare and aggressive cancer caused by exposure to toxic asbestos fibers.
The team includes medical oncologists, thoracic surgeons and radiation oncologists well versed in mesothelioma and who provide a personalized, multidisciplinary approach to care.
Diagnostic testing and much of the treatment for mesothelioma is performed at the General Oncology Clinic at SCCA. The nearby UW Medical Center handles surgical procedures and follow-up appointments.
SCCA recently opened a phase II mesothelioma clinical trial involving the immunotherapy drug durvalumab (MEDI4736) in combination with chemotherapy. It is designed as a first-line treatment of unresectable mesothelioma. Durvalumab is known as a monoclonal antibody that helps a patient’s own immune system attack tumor cells.
Goulart is chief investigator of the multicenter trial expected to run through 2020. Surgeons Farjah and Dr. Michael Mulligan perform much of the aggressive surgery that may include an extrapleural pneumonectomy or pleurectomy/decortication.
SCCA prides itself in being among the best facilities in the country. It attributes that status to a variety of factors that it promotes, including:
When patients complete treatment, SCCA continues to work tirelessly with them.
The Survivorship Clinic, which caters to cancer patients, offers support, treatment and education. SCCA emphasizes follow-up programs, and clinical studies for survivors and long-term follow-up care is offered to all patients.
Disclaimer: Seattle Cancer Care Alliance has no professional affiliation with Asbestos.com.
Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers. Read More